A multicenter collaborative study of genetic analysis using the Amoy Myeloid Panel, a specific gene genome sequencing kit, for patients with chronic myeloid leukemia in the chronic phase who are resistant or intolerant to existing tyrosine kinase inhibitors.

A multicenter collaborative study of genetic analysis using the Amoy Myeloid Panel, a specific gene genome sequencing kit, for patients with chronic myeloid leukemia in the chronic phase who are resistant or intolerant to existing tyrosine kinase inhibitors. - HM-SCREEN-Japan CML

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054812

Enrollment

Registered

2024-10-01

Start date

2024-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukemia chronic phase

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically or cytogenetically diagnosed with chronic myeloid leukemia. 2) Chronic phase at the time of enrollment. 3) Resistant or intolerant to two or more TKIs, and must be considering administering asciminib (regardless of whether or not they have subsequently been administered TKIs). 4) The age of majority as defined by the Civil Code and be able to give his/her consent.

Exclusion criteria

Exclusion criteria: 1) Attending physician judges to be inappropriate for enrollment in this study 2) History of asciminib administration

Design outcomes

Primary

Measure	Time frame
Concordance of the clinical course and the genomic information.	—

Secondary

Measure	Time frame
Assessment of the relationship between adverse events of treatment and gene mutation information	—

Countries

Japan

Contacts

Public ContactSeiichiro Katagiri

Tokyo Medical University Hospital Department of Hematology

katagiri@tokyo-med.ac.jp03-3342-6111

Outcome results